1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The successful completion of this trial could lead to the availability of a new semaglutide injection, potentially increasing access and offering more treatment options for Type 2 Diabetes patients. If the investigati…
This retrospective analysis holds significant potential to optimize current clinical treatment strategies for metabolic syndrome. By comparing the real-world effectiveness of established interventions like semaglutide…
This research holds significant promise for optimizing pediatric obesity treatment strategies, potentially leading to more accessible and sustainable interventions for a vulnerable population. The findings could redef…
This large-scale, pragmatic trial is crucial because it directly compares two leading therapeutic strategies for Type 2 Diabetes patients at high risk for cardiovascular and kidney complications. The findings could pr…
This pilot study holds significant promise, as successful integration of weight management strategies could potentially improve treatment efficacy and long-term outcomes for endometrial cancer patients. If tirzepatide…
This pilot study is crucial for understanding Tirzepatide's potential as a targeted therapy for MASLD, a condition with limited effective treatment options. Positive findings could pave the way for larger, more defini…
Finding effective strategies to prevent weight regain after discontinuing GLP-1 agonists is critically important for long-term obesity management and patient well-being. This trial could provide evidence for new stand…
Understanding the unique pathophysiology of Normal-Weight Type 2 Diabetes (NWD) is crucial, as these individuals may not benefit from traditional weight-loss-focused interventions for T2D. This study's findings could …
This Phase II trial is significant because it addresses a critical unmet need for effective weight management in adult survivors of childhood Acute Lymphoblastic Leukemia (ALL), a group highly susceptible to cardiomet…
This trial is critically important because it addresses a significant gap in our understanding of how tirzepatide performs in a vulnerable and growing patient group. The findings could establish a new therapeutic opti…
This groundbreaking GLP-1 brain atlas provides a foundational neuroanatomical map, offering unprecedented insights into the diverse physiological roles of GLP-1 beyond its well-known glucose-lowering effects. By preci…
This comprehensive synthesis underscores the critical role of inflammation as a shared, actionable therapeutic target for both cardiovascular disease and diabetes mellitus, moving beyond traditional single-disease app…
This study provides novel mechanistic insights into how Semaglutide exerts its therapeutic effects beyond simply delaying gastric emptying. Understanding these specific changes in gastric electrical activity could opt…
This study provides crucial evidence that a new, potentially more accessible semaglutide formulation can offer comparable efficacy and safety to the established reference drug for weight management. This could signifi…
This study underscores the immense public health implications of expanding semaglutide indications to include fibrotic MASH. It identifies a large, distinct, and currently underserved population with severe liver dise…
This study provides crucial real-world evidence that polyethylene glycol loxenatide is a highly effective and safe treatment option for Type 2 diabetes, offering comparable benefits to the widely used semaglutide. The…
This research highlights a novel therapeutic potential for Semaglutide beyond its established roles in diabetes and obesity, suggesting it could directly address cardiovascular complications associated with sarcopenia…
This study highlights that oral semaglutide not only manages blood glucose but also significantly reduces diabetes-related distress, thereby improving patient quality of life and potentially enhancing adherence to tre…
The analysis revealed a consistent and significant deficiency in the use of objective functional measures across studies investigating semaglutide in frail HFpEF populations. Many existing reports relied heavily on su…
This research provides crucial insights into the genetic underpinnings of GLP-1 RA response, paving the way for personalized treatment strategies. By identifying individuals most likely to benefit or experience advers…
This real-world evidence suggests that Tirzepatide could be a safe and effective therapeutic option for managing obesity and type 2 diabetes in kidney transplant recipients, a population often excluded from major clin…
This real-world study provides crucial evidence supporting the clinical benefit and safety of escalating once-weekly semaglutide from 0.5 mg to 1.0 mg in patients with Type 2 Diabetes. The significant improvements in …
If successful, this study could establish semaglutide as a safe and effective treatment option for glucose control in patients with Type 2 Diabetes and End Stage Renal Disease on dialysis. This is a particularly chall…
The findings from this trial are profoundly significant, as oral semaglutide offers a highly effective, non-injectable treatment option for Type 2 Diabetes Mellitus. This oral formulation has the potential to revoluti…
Understanding the safety and tolerability of BI 1820237 is a critical first step in its development as a potential new treatment for overweight and obesity. If BI 1820237 demonstrates a favorable safety profile and pr…
This trial addresses a significant gap in post-TAVR care, as current medical therapies do not adequately reduce long-term cardiovascular risks. If successful, this study could establish semaglutide as a crucial adjunc…
This research is crucial because it aims to provide a deeper understanding of how Semaglutide improves outcomes in Type 2 Diabetes beyond just weight loss and blood sugar control. By specifically targeting intramyocel…
This study addresses a critical need for practical, accessible dietary recommendations to complement GLP-1 RA therapy, potentially enhancing patient outcomes beyond just weight loss. If successful, it could provide a …
This study is pivotal as it explores a novel, multimodal approach to pre-surgical optimization for a high-risk patient population. If successful, the findings could revolutionize the standard of care for obese patient…
This study provides initial evidence that combining LY3457263 with tirzepatide could represent a more potent and effective strategy for treating obesity than existing monotherapies. The favorable safety profile and en…
This clinical trial is profoundly significant as it explores a novel and promising therapeutic approach for ADPKD, a disease with limited treatment options and a high burden on patients. If successful, this research c…
If successful, this pilot study could pave the way for a novel pre-surgical intervention to improve outcomes for prostate cancer patients. Demonstrating the feasibility of tirzepatide-assisted weight loss could lead t…
Had it been completed, this registry would have provided an invaluable real-world dataset for understanding the long-term trajectory of obesity and metabolic diseases, offering insights into how these conditions evolv…
If tirzepatide proves safe and effective, it could represent a significant therapeutic advancement for individuals with Type 1 Diabetes who struggle with obesity or overweight. Currently, there are limited pharmacolog…
This systematic review highlights the significant therapeutic potential of incretin-based therapies for individuals struggling with binge eating disorder, offering a promising new avenue for treatment. Given that curr…
This case report is crucial as it highlights a potential, albeit rare, adverse event associated with Tirzepatide that could have significant implications for patient safety and clinical practice. Given the widespread …
This study provides robust real-world evidence supporting the favorable cardiovascular safety profile of tirzepatide, particularly concerning heart failure and arrhythmias, in a diverse patient population. The consist…
This study provides crucial evidence that early intervention with tirzepatide and semaglutide can significantly mitigate the progression of atherosclerosis, a leading cause of morbidity and mortality worldwide. The ob…
This study provides compelling evidence that Semaglutide offers significant renoprotective benefits in a non-diabetic model of kidney injury, extending its potential therapeutic utility beyond metabolic diseases. The …
This case report provides compelling preliminary evidence suggesting a novel therapeutic avenue for Tirzepatide beyond its established metabolic indications. The observed improvements in autonomic dysfunction and POTS…